Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025
Ensysce Biosciences (NASDAQ:ENSC) released video highlights from its PAINWeek 2025 symposium titled "Pain Management, RE-Invented: A New Era for Analgesia", held in Las Vegas on September 3, 2025. The symposium featured medical and scientific leaders discussing challenges in pain treatment and Ensysce's proprietary platforms TAAP™ and MPAR®, which aim to reduce opioid misuse and overdose while preserving analgesia. Video highlights with expert commentary and real-world perspectives are available on the Ensysce Media/Science Center at www.ensysce.com.
The company said it continues advancing its portfolio toward commercialization with the goal of safer severe-pain management.
Ensysce Biosciences (NASDAQ:ENSC) ha pubblicato i video highlights dal suo simposio PAINWeek 2025 intitolato "Pain Management, RE-Invented: A New Era for Analgesia", tenutosi a Las Vegas il 3 settembre 2025. Il simposio ha visto leader medici e scientifici discutere delle sfide nel trattamento del dolore e delle piattaforme proprietarie di Ensysce TAAP™ e MPAR®, che mirano a ridurre l'abuso di oppioidi e le overdosi preservando al contempo l'analgesia. I video highlight, con commenti di esperti e prospettive reali, sono disponibili sul Ensysce Media/Science Center all'indirizzo www.ensysce.com.
L'azienda ha dichiarato di proseguire l'avanzamento del proprio portafoglio verso la commercializzazione con l'obiettivo di una gestione del dolore grave più sicura.
Ensysce Biosciences (NASDAQ:ENSC) publicó avances en video de su simposio PAINWeek 2025 titulado "Pain Management, RE-Invented: A New Era for Analgesia", celebrado en Las Vegas el 3 de septiembre de 2025. El simposio contó con líderes médicos y científicos que discutieron los desafíos en el tratamiento del dolor y las plataformas propietarias de Ensysce TAAP™ y MPAR®, que buscan reducir el uso indebido de opioides y las sobredosis sin perder la analgesia. Los avances en video con comentarios de expertos y perspectivas del mundo real están disponibles en Ensysce Media/Science Center en www.ensysce.com.
La empresa dijo que continúa avanzando su cartera hacia la comercialización con el objetivo de una gestión más segura del dolor severo.
Ensysce Biosciences (NASDAQ:ENSC)는 Las Vegas에서 2025년 9월 3일에 개최된 PAINWeek 2025 심포지엄의 영상 하이라이트를 발표했다. 제목은 "Pain Management, RE-Invented: A New Era for Analgesia"이며, 심포지엄에는 의료 및 과학 지도자들이 통증 치료의 도전과 Ensysce의 독자 플랫폼 TAAP™와 MPAR®를 논의했다. 이는 오피오이드 남용과 과다 복용을 줄이면서도 진통 효과를 보존하는 것을 목표로 한다. 전문가 해설과 실제 세계의 관점을 담은 영상 하이라이트는 www.ensysce.com의 Ensysce Media/Science Center에서 제공된다.
회사는 또한 안전한 중증 통증 관리의 목표를 향해 상용화를 향한 포트폴리오의 진전을 계속하고 있다고 밝혔다.
Ensysce Biosciences (NASDAQ:ENSC) a publié des extraits vidéo de son symposium PAINWeek 2025 intitulé "Pain Management, RE-Invented: A New Era for Analgesia", qui s'est tenu à Las Vegas le 3 septembre 2025. Le symposium a réuni des leaders médicaux et scientifiques discutant des défis du traitement de la douleur et des plateformes propriétaires d'Ensysce TAAP™ et MPAR®, destinées à réduire les abus et les overdoses d'opioïdes tout en préservant l'analgésie. Les extraits vidéo avec des commentaires d'experts et des perspectives réelles sont disponibles sur le Ensysce Media/Science Center à l'adresse www.ensysce.com.
La société a indiqué qu'elle poursuit l'avancement de son portefeuille vers la commercialisation dans le but d'une gestion plus sûre de la douleur sévère.
Ensysce Biosciences (NASDAQ:ENSC) hat Video-Highlights von seinem PAINWeek 2025-Symposium mit dem Titel "Pain Management, RE-Invented: A New Era for Analgesia" veröffentlicht, das in Las Vegas am 3. September 2025 stattfand. Das Symposium brachte medizinische und wissenschaftliche Führungskräfte zusammen, die Herausforderungen in der Schmerzbehandlung und Ensysces proprietäre Plattformen TAAP™ und MPAR® erörterten, die darauf abzielen, Opioidmissbrauch und Überdosierung zu reduzieren und gleichzeitig die Analgesie zu bewahren. Die Video-Highlights mit Expertenkommentaren und Real-World-Perspektiven sind im Ensysce Media/Science Center unter www.ensysce.com verfügbar.
Das Unternehmen sagte, es setze die Weiterentwicklung seines Portfolios in Richtung Kommerzialisierung fort, mit dem Ziel einer sichereren Behandlung schwerer Schmerzen.
إنسيسكي بيور سَينسز (ناسداك: ENSC) نشرت مقاطع فيديو مُلخصة من مؤتمر PAINWeek 2025 بعنوان "Pain Management, RE-Invented: A New Era for Analgesia"، الذي أُقيم في لاس فيغاس في 3 سبتمبر 2025. تَضَمَّنَ المؤتمر قادة طبيين وعلميين يناقشون التحديات في علاج الألم والمنصات الملكية لدى Ensysce TAAP™ و MPAR®، التي تهدف إلى تقليل سوء استخدام الأفيونيات وجرعاتها الزائدة مع الحفاظ على المسكنات. مقاطع الفيديو الملخصة مع تعليقات الخبراء ووجهات نظر العالم الواقعي متاحة على Ensysce Media/Science Center على www.ensysce.com.
قالت الشركة إنها تواصل دفع محفظتها نحو commercialization مع هدف إدارة الألم الشديد بشكل أكثر أماناً.
Ensysce Biosciences (NASDAQ:ENSC) 发布了其 PAINWeek 2025 研讨会的高清视频亮点，题为 "Pain Management, RE-Invented: A New Era for Analgesia"，于 2025年9月3日 在拉斯维加斯举行。研讨会邀请医疗和科学领域领袖讨论疼痛治疗中的挑战，以及 Ensysce 的专有平台 TAAP™ 与 MPAR®，旨在在保持镇痛效果的同时减少阿片类药物的滥用和致死风险。带有专家评论和真实世界观点的视频亮点可在 www.ensysce.com 的 Ensysce Media/Science Center 查看。
公司表示将继续推进其产品组合走向商业化，目标是更安全的重度疼痛管理。
- None.
- None.
~ Pain Management, RE-Invented: Ushering in a New Era for Analgesia ~
SAN DIEGO, CA, CA / ACCESS Newswire / October 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain therapeutics designed to minimize abuse and overdose risk, has released video highlights from its widely attended symposium at PAINWeek2025, the world's largest pain management conference.
The event, titled "Pain Management, RE-Invented: A New Era for Analgesia," was held in Las Vegas on September 3, 2025, and featured a distinguished panel of medical and scientific leaders. Together, they examined the urgent challenges in today's pain treatment landscape and the promising potential of Ensysce's proprietary platforms, TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance).
These breakthrough technologies aim to redefine opioid safety by preventing misuse and overdose while maintaining effective pain relief - a critical advancement as the opioid crisis continues to impact communities globally.
Video highlights from the symposium including expert commentary, real-world insights, and future outlooks are now available here and on the Ensysce Media / Science Center at www.ensysce.com.
"PAINWeek is the flagship event for pain specialists, and we were honored by the strong engagement at our symposium," said Dr. Lynn Kirkpatrick, CEO of Ensysce Biosciences. "We're excited to share key moments from this important discussion as we continue advancing our portfolio toward commercialization, with the goal of transforming how severe pain is safely managed."
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. For more information, please visit www.ensysce.com.
Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, possible NASDAQ delisting, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; continuation of government funding; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, available free of charge at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us
SOURCE: Ensysce Biosciences
View the original press release on ACCESS Newswire
FAQ
What did Ensysce (ENSC) present at PAINWeek 2025 on September 3, 2025?
Where can investors and clinicians watch Ensysce PAINWeek 2025 video highlights for ENSC?
What are TAAP™ and MPAR® discussed by Ensysce (ENSC) at PAINWeek 2025?
Does Ensysce say the PAINWeek symposium advances its commercialization timeline for ENSC products?
Who spoke at Ensysce's PAINWeek 2025 symposium referenced by ENSC?
